Regulatory Approval

Bausch + Lomb's EyeGility system aims to make cataract surgery faster and safer. A look at the tech, the competition, and the push for efficiency.

As demand for battle-proven drones soars, AIRO’s major RQ-35 delivery proves that controlling the entire supply chain is the key to winning in defense.

Graphite One's Ohio facility clears a key regulatory hurdle, accelerating a plan to build the first fully integrated US graphite supply chain.

With mortality rates over 50%, cardiogenic shock has long eluded targeted treatment. Now, a novel antibody from 4TEEN4 gets an FDA fast track.

As Europe's MiCA regulation wipes out 90% of crypto firms, Singaporean-founded Paymonade emerges as a key builder of the new, compliant financial plumbing.

In a landmark move, DTCC successfully tokenized U.S. securities, proving institutional finance can adopt blockchain to unlock unprecedented market liquidity.

A new bispecific antibody from Kelun-Biotech and Harbour BioMed just got a green light in China, promising quarterly doses for asthma. Is this the innovation that finally unseats the market giants?

Genentech's Gazyva gains FDA Priority Review for a rare kidney disease with no approved treatments, signaling a potential paradigm shift for patients.

With new launches in Austin and Cleveland and a C-suite of Tesla, Waymo, and Uber vets, Zipline is rapidly scaling its autonomous delivery empire.

With a new one-hour test for deadly bloodstream infections, QIAGEN aims to arm clinicians in the fight against sepsis and antimicrobial resistance.

A key approval for a single raw material in Japan reveals the new frontier in biopharma: a global race for regulatory compliance that could fast-track cell therapies.

As AT&T plans to end new landline orders in California, a fierce debate erupts over public safety, consumer choice, and the future of essential services.

A small firm aims to build the first US uranium mill in 40 years, pitting national energy security and AI's power needs against a legacy of environmental risk.

A small U.S. med-tech firm is targeting China's massive cervical cancer screening market. Can its innovative device navigate the regulatory maze for a huge payoff?

Vesalio poaches a Philips commercial leader to scale its innovative clot-removal platform. This strategic hire signals a major offensive in a rapidly growing market.

As Olin and Huntsman clear a key SEC hurdle, the strategic rationale behind their merger comes into focus: a calculated move to build a resilient, vertically integrated powerhouse.

In a Texas suburb, a network of smart defibrillators and citizen volunteers beat EMS to a cardiac arrest scene. It’s a look at the future of emergency response.

Atrium Therapeutics' clinical trial for a rare cardiomyopathy isn't just a milestone; it's a strategic maneuver signaling the arrival of precision RNA therapies in cardiology.

With ASTM approval secured and mandates looming, Argus Media's new methanol-to-jet index provides the pricing transparency needed to fuel aviation's costly green transition.

Milla Pharmaceuticals' new FDA approval for a vital acidosis drug offers hope for hospitals battling chronic shortages and marks a key strategic win for parent A.forall.